中国P站

Obesity; Type 2 Diabetes; Diabesity; Inflammation; Insulin Resistance; Gut Microbiota; Pharmacotherapy; Bariatric Surgery; Lifestyle Interventions; Epigenetics; Mitochondrial Dysfunction; Metabolic Dysfunction

Introduction

This review explores the intricate connections between obesity, type 2 diabetes, and cardiovascular disease, highlighting the critical roles of chronic inflammation, insulin resistance, and alterations in the gut microbiota. These factors collectively contribute to the progression of "diabesity" and its associated complications, emphasizing potential therapeutic targets for intervention [1].

Delving into molecular mechanisms, another review explains how excess adiposity drives diabetic pathogenesis. This involves pathways like insulin resistance, chronic low-grade inflammation, adipose tissue dysfunction, and hormonal imbalances, providing a comprehensive overview of how obesity underpins type 2 diabetes [2].

Modern pharmacotherapeutic strategies for managing "diabesity" are also discussed, presenting novel and emerging drug classes. The review details their mechanisms of action, efficacy in weight loss and glycemic control, and considerations for personalized treatment approaches, reflecting the evolving landscape of medical management [3].

The significant role of the gut microbiome in the development and progression of obesity and diabetes is explored, detailing how dysbiosis, changes in microbial composition, and metabolites influence host metabolism, energy balance, insulin sensitivity, and inflammation, thereby contributing to the "diabesity" phenotype [4].

Surgical interventions, specifically bariatric surgery, are reviewed for their efficacy in treating type 2 diabetes in obese patients. These procedures lead to significant weight loss, improved glycemic control, and often diabetes remission, highlighting their role as a powerful therapeutic option for "diabesity" [5].

The central role of adipose tissue inflammation in mediating the link between obesity and metabolic dysfunction, including insulin resistance and type 2 diabetes, is also highlighted. The cellular and molecular mechanisms driving this inflammation are identified, alongside potential therapeutic targets to interrupt the progression from obesity to diabetes [6].

Furthermore, the profound influence of gut hormones and their signaling pathways on the pathogenesis of obesity and type 2 diabetes is investigated. Key gut peptides regulate appetite, energy expenditure, glucose homeostasis, and insulin secretion, positioning them as potential therapeutic targets for "diabesity" management [7].

The fascinating field of epigenetics reveals how changes in gene expression, without altering DNA sequence, contribute to type 2 diabetes in obese individuals. Mechanisms like DNA methylation, histone modification, and non-coding RNAs serve as crucial links between environmental factors, obesity, and diabetes risk [8].

Mitochondrial dysfunction is presented as another pivotal link connecting obesity with type 2 diabetes. Impaired mitochondrial function, especially in insulin-sensitive tissues, contributes to insulin resistance, altered lipid metabolism, and increased oxidative stress, driving the progression of "diabesity" [9].

Finally, the efficacy of various lifestyle interventions, including dietary changes, increased physical activity, and behavioral modifications, in the comprehensive management of obesity and type 2 diabetes is examined. These foundational strategies are crucial for improving weight, glycemic control, and overall metabolic health, serving as primary prevention and treatment for "diabesity" [10].

Description

The intricate relationship between obesity, type 2 diabetes, and cardiovascular disease, frequently termed "diabesity," represents a major global health challenge. This complex interplay is largely driven by a cascade of molecular and physiological dysfunctions. Key among these are chronic inflammation, persistent insulin resistance, and significant alterations within the gut microbiota. These core factors synergistically contribute to the progressive development of "diabesity" and its severe associated complications, underscoring the necessity for targeted therapeutic strategies [1]. The underlying molecular mechanisms are diverse, encompassing how excessive adiposity directly contributes to diabetic pathogenesis through pathways such as insulin resistance, a state of reduced cellular response to insulin, coupled with chronic low-grade systemic inflammation. Further contributions arise from dysfunction in adipose tissue itself and various hormonal imbalances that disrupt metabolic homeostasis, providing a comprehensive understanding of the strong association between excess body fat and type 2 diabetes [2, 6].

Expanding on the intricate mechanisms, the gut microbiome plays a profoundly significant role in both the development and progression of obesity and diabetes. Dysbiosis, characterized by detrimental shifts in microbial composition and the metabolic byproducts they produce, exerts considerable influence on host metabolism, affecting energy balance, insulin sensitivity, and systemic inflammation. This microbial dysregulation is a critical driver behind the "diabesity" phenotype [4]. Concurrently, adipose tissue inflammation holds a central position in mediating the connection between obesity and widespread metabolic dysfunction, including the onset of insulin resistance and type 2 diabetes. Understanding the specific cellular and molecular pathways that fuel this inflammation is crucial for identifying viable therapeutic targets to effectively interrupt the progression from an obese state to overt diabetes [6].

Moreover, the profound influence of gut hormones and their complex signaling pathways cannot be overstated in the pathogenesis of both obesity and type 2 diabetes. Essential gut peptides are instrumental in regulating critical physiological processes such as appetite control, overall energy expenditure, maintaining glucose homeostasis, and influencing insulin secretion. Recognizing these powerful regulatory roles highlights their immense potential as therapeutic targets for comprehensive "diabesity" management [7]. Beyond these, emerging research points to epigenetic mechanisms as crucial links. These involve changes in gene expression, such as DNA methylation and histone modification, that occur without altering the underlying DNA sequence. Such modifications, along with the action of non-coding RNAs, are seen as pivotal in connecting environmental factors and obesity to an elevated risk of developing type 2 diabetes [8]. Similarly, mitochondrial dysfunction is identified as another critical link between obesity and the development of type 2 diabetes. Impaired mitochondrial function, particularly within insulin-sensitive tissues, contributes significantly to insulin resistance, leads to altered lipid metabolism, and increases oxidative stress, thereby accelerating the progression of "diabesity" [9].

Addressing this complex condition necessitates a multi-pronged therapeutic approach. Modern pharmacotherapeutic strategies offer a promising avenue, with novel and emerging drug classes designed to tackle both weight loss and glycemic control. These treatments are characterized by distinct mechanisms of action and varying efficacies, prompting a shift towards personalized treatment approaches to optimize patient outcomes in the evolving landscape of medical management [3]. Furthermore, surgical interventions, particularly bariatric surgery, have demonstrated remarkable efficacy. These procedures lead to substantial weight reduction, marked improvements in glycemic control, and frequently result in the remission of type 2 diabetes, firmly establishing bariatric surgery as a powerful and often definitive therapeutic option for "diabesity" [5].

Crucially, foundational lifestyle interventions remain paramount in the comprehensive management of obesity and type 2 diabetes. These interventions include structured dietary changes, consistent increases in physical activity, and targeted behavioral modifications. Such strategies are vital for significantly improving weight status, enhancing glycemic control, and fostering overall metabolic health. They serve not only as primary preventative measures but also as fundamental treatments for "diabesity," highlighting the enduring importance of patient-centered, holistic care [10].

Conclusion

The literature explores the intricate relationship between obesity, type 2 diabetes, and cardiovascular disease, collectively termed "diabesity." Key mechanisms driving this connection include chronic inflammation, insulin resistance, and alterations in the gut microbiota. Molecular pathways further elucidate how excess adiposity leads to diabetic pathogenesis through adipose tissue dysfunction, hormonal imbalances, epigenetics, and mitochondrial dysfunction. The gut microbiome’s role in influencing host metabolism, energy balance, and insulin sensitivity is also a significant factor in the "diabesity" phenotype. Therapeutic approaches range from modern pharmacotherapy, which introduces novel drug classes for weight management and glycemic control, to surgical interventions like bariatric surgery, which offers significant weight loss and diabetes remission. Importantly, lifestyle interventions, including dietary changes, increased physical activity, and behavioral modifications, are highlighted as foundational strategies for prevention and comprehensive management. These insights collectively emphasize the complex biological underpinnings of "diabesity" and highlight diverse intervention points from molecular pathways to lifestyle and surgical management.

References

1. Shahar T, Yair E, Yael R (2023) .Biomedicines 11:3281.

   , ,

2. Nivedita S, Neha S, Sanjana Y (2022) .J Diabetes Metab Disord 21:433-441.

   , ,

3. Caroline MA, Daniel D, Vanitha RA (2024) .Clin Chem 70:236-247.

   , ,

4. Min Z, Peng S, Lin Y (2021) .Front Endocrinol (Lausanne) 12:782013.

   , ,

5. Yulia VV, Marina MK, Natalya IS (2020) .Diabetes Mellitus 23:541-550.

   , ,

6. Mariya DS, Olga KZ, Alexander VP (2023) .Biomedicines 11:1730.

   , ,

7. Sarah KM, Erin EM, Michael KH (2022) .Cells 11:2590.

   , ,

8. Elodie L, Chloé D, Audrey J (2021) .Curr Diab Rep 21:59.

   , ,

9. Laura C, Marina MCG, Rodrigo TC (2019) .Curr Pharm Des 25:3772-3784.

   , ,

10. Sarah AJ, Robert LS, Emily RW (2024) .Nutr Metab (Lond) 21:17.

    , ,